参考文献
(在框内滑动手指即可浏览)
[1] Zeng H,Chen W,Zheng R,et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries [J]. Lancet Glob Health,2018,6(5):e555-e567.
[2] Strobel O,Neoptolemos J,Jäger D,et al. Optimizing the outcomes of pancreatic cancer surgery [J]. Nat Rev Clin Oncol,2019,16(1):11-26.
[3] National Comprehensive Cancer Network. NCCN. Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma,Version 1.2021 [EB/OL]. http://www..
[4] Zhan HX,Xu JW,Wu D,et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies [J]. Cancer Med,2017,6(6):1201-1219.
[5] Jang JY,Han Y,Lee H,et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective,randomized,open-label,multicenter phase 2/3 trial [J]. Ann Surg,2018,268(2):215-222.
[6] Versteijne E,Suker M,Groothuis K,et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial [J]. J Clin Oncol,2020,38(16):1763-1773.
[7] Kim EJ,Ben-Josef E,Herman JM,et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer [J]. Cancer,2013,119(15):2692-2700.
[8] Chu LC,Goggins MG,Fishman EK. Diagnosis and detection of pancreatic cancer [J]. Cancer J,2017,23(6):333-342.
[9] Daamen LA,Groot VP,Goense L,et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis [J]. Eur J Radiol,2018,106:128-136.
[10] Yeh R,Dercle L,Garg I,et al. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma [J]. Abdom Radiol (NY),2018,43(2):415-434.
[11] Marion-Audibert AM,Vullierme MP,Ronot M,et al. Routine MRI with DWI sequences to detect Liver metastases in patients with potentially resectable pancreatic ductal carcinoma and normal liver CT: A prospective multicenter study [J]. Am J Roentgenol,2018,211(5): W217-W225.
[12] 边云,陆建平. 胰腺癌影像学进展与思考 [J]. 放射学实践,2020,35(1):20-26.
[13] Gilbert JW,Wolpin B,Clancy T,et al. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification [J]. Ann Oncol,2017,28(9):2067-2076.
[14] Han S,Jin G,Wang L,et al. The role of PAM4 in the management of pancreatic cancer: diagnosis,radioimmunodetection,and radioimmunotherapy [J]. J Immunol Res,2014,2014:268479.
[15] Rong D,Mao Y,Hu W,et al. Intravoxel incoherent motion magnetic resonance imaging for differentiating metastatic and non-metastatic lymph nodes in pancreatic ductal adenocarcinoma [J]. Eur Radiol,2018,28(7):2781-2789.
[16] Scali EP,Walshe T,Tiwari HA,et al. A Pictorial review of hepatobiliary magnetic resonance imaging with hepatocyte-specific contrast agents: uses,findings,and pitfalls of gadoxetate disodium and gadobenate dimeglumine[J]. Can Assoc Radiol J,2017,68(3):293-307.
[17] Allen VB,Gurusamy KS,Takwoingi Y,et al. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer [J]. Cochrane Database Syst Rev,2016,7(7):CD009323.
[18] Suker M,Koerkamp BG,Coene PP,et al. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases [J]. Eur J Surg Oncol,2019,45(10):1906-1911.
[19] Jeune F,Coriat R,Prat F,et al. Pancreatic cancer surgical management [J]. Presse Med,2019,48(3 Pt 2):e147-e158.
[20] Katz MH,Fleming JB,Bhosale P,et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators [J]. Cancer,2012,118(23):5749-5756.
[21] Cassinotto C,Cortade J,Belleannée G,et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment [J]. Eur J Radiol,2013,82(4):589-593.
[22] Barreto SG,Loveday B,Windsor JA,et al. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer [J]. ANZ J Surg,2019,89(5):481-487.
[23] Beleù A,Calabrese A,Rizzo G,et al. Preoperative imaging evaluation after downstaging of pancreatic ductal adenocarcinoma: A multi-center study[J]. Cancers (Basel),2019,11(2):267.
[24] Ferrone CR,Marchegiani G,Hong TS,et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer [J]. Ann Surg,2015,261(1):12-17.
[25] Bali MA,Metens T,Denolin V,et al. Tumoral and nontumoral pancreas: correlation between quantitative dynamic contrast-enhanced MR imaging and histopathologic parameters [J]. Radiology,2011,261(2):456-466.
[26] Jutric Z,Melstrom LG. New Treatment options and management considerations in borderline resectable pancreatic cancer [J]. Oncology (Williston Park),2017,31(6):443-452.
[27] Scheufele F,Hartmann D,Friess H. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer [J]. Transl Gastroenterol Hepatol,2019,4:32.
[28] Yang R,Lu M,Qian X,et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review [J]. J Cancer Res Clin Oncol,2014,140(12):2077-2086.
[29] Tamburrino D,Riviere D,Yaghoobi M,et al. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer [J]. Cochrane Database Syst Rev,2016,9(9):CD011515.
[30] Ehrlich D,Ather N,Rahal H,et al. The utility of EUS-FNA to determine surgical candidacy in patients with pancreatic cancer after neoadjuvant therapy [J]. J Gastrointest Surg,2020,24:2807-2813.
[31] Matsui T,Nishikawa K,Yukimoto H,et al. Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a report of two cases [J]. World J Surg Oncol,2019,17(1):134.
[32] Aoki S,Motoi F,Murakami Y,et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients [J]. BMC Cancer,2019,19(1):252.
[33] Hartwig W,Strobel O,Hinz U,et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy [J]. Ann Surg Oncol,2013,20(7):2188-2196.
[34] Luo G,Xiao Z,Long J,et al. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer [J]. J Gastrointest Surg,2013,17(12):2092-2098.
[35] Kim YC,Kim HJ,Park JH,et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? [J]. J Gastroenterol Hepatol,2009,24(12):1869-1875.
[36] Kiliç M,Göçmen E,Tez M,et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer [J]. Can J Surg,2006,49(4):241-244.
[37] Santucci N,Facy O,Ortega-Deballon P,et al. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients [J]. Pancreatology,2018,18(6):666-670.
[38] van Veldhuisen E,Vogel JA,Klompmaker S,et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy [J]. HPB (Oxford),2018,20(7):605-611.
[39] Macedo FI,Ryon E,Maithel SK,et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/Nab-paclitaxel chemotherapy in resected pancreatic cancer [J]. Ann Surg,2019,270(3):400-413.
[40] Liu GF,Li GJ,Zhao H. Efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic cancer: A network Meta-analysis [J]. J Cell Biochem,2018,119(1):511-523.
[41] Stein SM,James ES,Deng Y,et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer [J]. Br J Cancer,2016,114(7):737-743.
[42] 中国研究型医院学会消化道肿瘤专业委员会,中国医师协会外科医师分会多学科综合治疗专业委员会. 胰腺癌多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志,2017,37(1):35-36.
[43] Kirkegård J,Aahlin EK,Al-Saiddi M,et al. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation[J]. Br J Surg,2019,106(6):756-764.
[44] Hansen MFC,Storkholm JH,Hansen CP. The results of pancreatic operations after the implementation of multidisciplinary team conference (MDT): A quality improvement study[J]. Int J Surg,2020,77:105-110.
[45] Michelakos T,Pergolini I,Castillo CF,et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX [J]. Ann Surg,2019,269(4):733-740.
[46] Speicher MR,Pantel K. Tumor signatures in the blood [J]. Nat Biotechnol,2014,32(5):441-443.